tribio6k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2016
Commission File Number: 000-22320
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow
Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
The following exhibit is attached:
|
Exhibit No.
|
|
Description of Exhibit
|
|
99.1
|
|
Press release: Trinity Biotech Announces withdrawal of Troponin FDA 510(k) Submission
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
TRINITY BIOTECH PLC
|
| |
|
| |
|
| |
By:
|
/s/Kevin Tansley
|
| |
|
Kevin Tansley
|
| |
|
Chief Financial Officer
|
Date: November 18, 2016
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
Press release: Trinity Biotech Announces withdrawal of Troponin FDA 510(k) Submission
|
| |
|